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uncomplicated bone metastases. Actually, no evidence based 
recommendations are available for the treatment of 
complicated bone metastases. This study was conducted to 
evaluate the effectiveness in term of symptom control of a 
SHort course Accelerated RadiatiON therapy (SHARON study) 
in the treatment of patients with complicated bone 
metastases. 
Materials and Methods: A phase II clinical trial was designed. 
Patients with complicated bone metastases metastases, and 
Eastern Cooperative Oncology Group (ECOG) performance 
status < 3 were included. Treatment was delivered in two 
days with a twice daily fractionation and at least an eight 
hour interval at 20 Gy (5 Gy per fraction). The primary 
endpoint was the assessment of efficacy in terms of pain 
relief. 
Results: Characteristics of the 25 enrolled patients were: 
male/female: 14/11; median age: 65 years (range, 45 to 85 
y). The site of the primary tumor was: lung (36%), breast 
(32%), prostate (12%), kidney (8%), rectum (4%), thyroid (4%), 
and uterus (4%). All patients had pain at the time of 
treatment. Three weeks after treatment, the response of 
pain was evaluated by visual analogue scale (VAS). 23 of the 
25 symptomatic patients had improvement or resolution of 
pain based (overall response rate to the symptom: 92.5% CI 
0.95: 68.68% - 99.13). Specifically, 8 patients (32%) had 
complete resolution of pain, 15 patients (60%) had a partial 
response and 2 patients (8%) remained stable. A statistically 
significant reduction in pain assessed by VAS, was recorded 
(pre-treatment vs. post-treatment mean VAS = 5.9±2.6 vs. 
2.7±2.5; p = 0.039). Only 1 patient required retreatment at 
12 months. In addition, 18 of the 25 patients (72%) showed 
improvement or stability ECOG. Only acute toxicities of grade 
1 and 2 were recorded: skin G1 =16%, hematological (anemia) 
G1 = 4%, gastro-intestinal G1 (diarrhea) = 4%, gastrointestinal 
(nausea and vomiting) G2 =8%. 
Conclusions: Short course accelerated radiotherapy of 20 Gy 
BID in two consecutive days is effective in term of symptoms 
relief. These results justify a phase III comparison against the 
standard-of-care in these patients’ population (30 Gy in 10 
fractions). 
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Purpose/Objective: Recent technology of diagnosis has 
increased prevalence of oligometastatic patients. 
Stereotactic body radiotherapy (SBRT) to oliogometastases 
showed outstanding local control but also promising overall 
survival. Though liver oliogmetastses is a most common site 
for surgery, above 70% of these patients are unresectable. An 
effective and safe local modality option is necessary for 
these patients. We analyzed outcomes and toxicity for 
patients with liver oligometastases treated by SBRT from 
variable tumors. 
Materials and Methods: Seventy-two patients with liver 
oligometastases from 2002 to 2013 were treated by SBRT 
consecutively. Among them, 17 patients excluded; un-
controllable distant metastases in 9 patients and immediate 
follow-up loss after treatment in 8 patients. A total of 55 
patients with 77 lesions were analyzed retrospectively. 
Primary lesion of all patients was controlled, the patients 
with stable lesions in another site in 28 patients. The most 
common primary organ was colon in 36 patients followed by 
the stomach 6 patients, and other 13 patients. The tumor 
volume was calculated by sum of total GTV. The median 
volume was 20 cc (0.7-721.2 cc). Thirty-eight (69%) of the 
patients had a single metastatic lesion. Total SBRT dose was 
from 30 to 60 Gy (median 48 Gy) by 3-4 fractions. Thirty-nine 
(72%) of the patients received chemotherapy as part of their 
primary treatment. Toxicity was evaluated by Common 
Toxicity Criteria for Adverse Events Version 4.0 Grading 
scale. 
Results: The 2 and 5-year overall survival rate was 56% and 
20%, respectively. Actuarial 2 year local control and 
progression free survival rate were 60% and 22%, 
respectively. Grade 1-2 fatigue, nausea, and vomiting were 
the most common adverse events, and no grade 3 and higher 
adverse events were observed. By multivariate analysis 
according to survival, other visible lesion was a statistically 
significant factor. 
Conclusions: SBRT for liver oligometastases seems to be safe. 
High SBRT dose is correlated with high local control. To 
obtain survival gain through SBRT among patients with 
oligorecurrence, criteria of optimal candidate is mandatory. 
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Purpose/Objective: 8 Gy single fraction (flash) conventional 
external beam radiation therapy is the most commonly 
administered single fraction dose and is considered the 
standard treatment for uncomplicated bone metastases. 
However, its efficacy is uncertain in patients with bone 
metastases involving the adjacent soft tissues. Aim of the 
study was to evaluate the flash efficacy in terms of pain 
control for this particular patient setting. 
Materials and Methods: An observational study of patients 
treated with Radiotherapy for bone metastases was 
conducted from January 2003 to December 2010 in our 
Department. The study included patients with painful bone 
metastases of any primary sites and any ECOG performance 
status < 4. Eight Gray single fraction conventional external 
beam radiation therapy (3DCRT) was administered. Patients 
were evaluated for pain with visual-analogue scale (VAS) 
before and 3 weeks after irradiation. Pain response was 
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classified according to the categories of Chow (IJROBP, 
2012). 
Results: 248 consecutive patients (Male/Female: 144/104; 
median age: 68 years;range:27-94 years) were included in the 
study. On the basis of radiological exams and CT simulation, 
86% of the patients (214/248) had no extra-osseous extension 
compared to 14% (24/248) that presented bone disease with 
involvement of the adjacent soft tissues. All the patients 
were symptomatic for pain at the time of treatment. Three 
weeks later, 44% of the patients (109/248) showed pain 
reduction or resolution. In detail, 58 patients (23.5%) 
obtained a complete response (CR), 51 (20.5%) a partial 
response (PR), 63 (25%) no response to treatment (pain 
worsening) and 76 (30%) had an unspecified response. A 
statistically significant pain reduction was reported (pre- vs 
post-RT mean VAS: 4.6 versus 3.7; p=0.0001). CR rate (table 
1, p:0.678) as well CR+PR rate (p:0.274) were not 
significantly associated with extra-osseous extension. 
 
 
 
Conclusions: The efficacy of 8 Gy single fraction schedule 
was confirmed in terms of pain control even in patients with 
bone metastases with extension to soft tissues. The relatively 
low analgesic response is likely due to the administering of 
analgesic drugs before irradiation in the majority of cases. 
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Purpose/Objective: To evaluate and to compare the 
dosimetric features of static and volumetric intensity-
modulated radiotherapy (IMRT) for brain oligometastases 
hypofractionated stereotactic treatment, focusing on the 
dosimetric comparison between the single and multiple 
isocenters modalities for multiple contiguous brain 
metastases.  
Materials and Methods: Patients with single or multiple brain 
metastases, in the same lobe or contiguous, treated by 
hypofractionated stereotactic RT in our Institution were 
enrolled. For each patient 2 treatment plans were 
performed: a static (5 fields) and a volumetric (2 arcs) IMRT 
plans. For patient with multiple brain metastases, each plan 
was performed in 2 different modalities: single and multiple 
isocenters. The PTV was the lesion + 3 mm. In single 
isocentre modality plans, for patients with multiple lesions, 
the definitive PTV was the PTV sum of each single lesion. The 
prescribed dose to lesions was 25.5 Gy/3fr. Plans were 
evaluated for: monitor units (UM); Conformity Index (CI); 
Homogeneity Index (HI); Paddick Conformity Index (PCI); 
Gradient Index (GI); normal brain mean dose; brainstem, 
optic chiasm, optic nerves maximum dose; EQD2 
hyppocampus mean dose. Dose-volume histograms were 
compared by Friedman test. 
Results: Thirteen patients were included in the analysis, 7 
patients with a solitary lesion, 6 patients with multiple (2-3) 
metastases in the same lobe or contiguous, with a total of 20 
treated lesions. The median CTV was 0.71 cm3 (range, 0.21-
5.26), median PTV was 4.7 cm3 (range, 1.5-18.47). Median 
mean dose to normal brain tissue was 1.79 (0.68-6.27) for 
volumetric IMRT and 1.92 (0.69-8.70) for static IMRT (p: 
0.024). Among the 6 oligometastatic patients, a total of 13 
lesions was analyzed. For multiple isocenters modality plans 
median CTV was 0.53 cm3 (0.21-3.27), median PTV was 3.64 
cm3 (1.49-18.47). For single isocentre modality median CTV 
was 1.59 cm3 (0.47-5.95), median PTV 10.68 cm3 (2.99-
27.08). Median mean dose to normal brain tissue was 3.72 
(1.80-5.84) and 3.52 (2.49-5.67) for static IMRT in single and 
multiple modality, respectively, 3.84 (2.41-6.27) and 3.22 
(2.02-5.31) for volumetric IMRT in single and multiple 
isocentre modality, respectively (p:0.009). Median GI for 
static IMRT plans was 1.62 (1.40-2.05) and 1.50 (1.30-1.70) in 
single and multiple isocentre modality respectively, 1.60 
(1.25-1.95) and 1.35 (1.15-1.60) for volumetric IMRT plans in 
single and multiple isocentre modality respectively (p: 
0.024). None of the other studied parameters resulted in 
significant differences.  
Conclusions: In our experience static and volumetric IMRT 
are both efficient techniques for intensity modulated 
hypofracionated stereotactic treatment. Volumetric IMRT 
seems to results in lower normal brain dose in single 
isocenter modality; multiple isocenters modality seems to 
reduce normal brain irradiation in treating multiple 
contiguous lesions.  
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Purpose/Objective: Stereotactic Ablative Body Radiotherapy 
(SABR) has emerged as a novel treatment modality for local 
extracranial metastases such as lymph node oligometastases 
with promising clinical results. This study aims to investigate 
the relationship between dosimetric parameters of SABR and 
treatment outcomes for patients with unresectable nodal 
metastases. 
Materials and Methods: A retrospective review of SABR 
patients who were treated using a Cyberknife unit at our 
institution was carried out to determine each patient's 
Progression Free Survival (PFS) and Overall Survival (OS). 
Patient's demographic data including age, anatomical 
location of sites treated and histopathology of primary 
disease were reviewed. Assuming a/ß=10 for tumour control, 
dosimetric parameters including biological equivalent doses 
(BED) of prescription dose, minimum dose and mean dose to 
GTV and PTV (GTVmin, GTVmean, PTVmin and PTVmean) 
